Antheia Secures $80 Million Conditional Funding Commitment from Department of War’s Office of Strategic Capital
Financing supports Antheia’s domestic manufacturing strategy to onshore critical medicine supply chains MENLO PARK, CA – October 18, 2026 – Antheia, the advanced biosynthesis company delivering 21st-century pharmaceutical manufacturing and innovation, today announced it has received a conditional commitment from the U.S. Department of War’s Office of Strategic Capital (OSC) for a direct, long-term loan […]